Welcome to our dedicated page for REMEGEN CO UNSP/ADR news (Ticker: REGMY), a resource for investors and traders seeking the latest updates and insights on REMEGEN CO UNSP/ADR stock.
RemeGen Co. Ltd. is a commercial-stage biotechnology company based in Yantai, China. Established in 2008, the company is a leader in providing solutions for patients with life-threatening illnesses through innovative biologic drugs. RemeGen focuses on therapeutic areas such as autoimmune diseases, oncology, and ophthalmic conditions, with a commitment to research, development, and commercialization.
RemeGen has gained recognition for its proprietary antibody-drug conjugates (ADCs), including Disitamab Vedotin (RC48) and RC88, targeting various solid tumors with high unmet medical needs. These innovative drugs have shown promising results in clinical trials, offering new hope for patients worldwide.
Rhea-AI Summary
RemeGen Co. Ltd. has announced three major developments in the fight against cancer, including advancements in cancer drug research and new treatment options for cervical cancer, advanced malignant entities, and HER2-expressing advanced gastric cancer. These developments aim to provide more effective and safer treatment options for cancer patients around the world.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
News
Rhea-AI Summary
RemeGen Co. Ltd. (9995.HK, 688331.SH) announced that its mesothelin-targeting antibody-drug conjugate, RC88, has been granted Fast Track Designation by the FDA for the treatment of platinum-resistant recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancers. RC88 has shown promising results in terminating tumor cells with various expression levels of MSLN, offering a novel approach to this challenging medical condition.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
RemeGen Co. Ltd. (9995.HK, SHA: 688331) has confirmed the inclusion of Telitacicept and Disitamab Vedotin on the National Reimbursement Drug List (NRDL) under the 2023 simple renewal mechanism of China National Healthcare Security Administration (NHSA). This achievement signifies a significant milestone for RemeGen in the innovative pharmaceutical industry and highlights its prominent position in the market. Sales of these drugs surged by 1780% and 1513% for Telitacicept and Disitamab Vedotin, respectively, compared to the preceding year, showcasing their growing popularity and effectiveness among patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
RemeGen Co. Ltd. (9995.HK, SHA: 688331) announced positive results from two Phase II trials of Disitamab Vedotin for HER2-positive locally advanced or metastatic urothelial carcinoma. The drug demonstrated consistent efficacy and manageable safety profiles, leading to its conditional approval in China.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
RemeGen Co., Ltd. (HKG: 9995, SHA: 688331) is set to present telitacicept Phase III Clinical Trial Results for Rheumatoid Arthritis Patients at the American College of Rheumatology (ACR) Convergence 2023. The study demonstrated the efficacy and safety of telitacicept 160 mg group compared to the placebo group in RA patients with inadequate responses to MTX. This follows positive results in a Phase III clinical study in China for the innovative drug telitacicept, which independently developed by RemeGen, targeting B-cell lymphocyte stimulation and proliferation inducing ligands (BLyS/APRIL) to treat various immunology diseases mediated by B cells.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
RemeGen's Telitacicept shows positive results in Phase III study for rheumatoid arthritis treatment in China
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
RemeGen Co., Ltd. (HKG: 9995, SHA: 688331) has announced the publication of their Phase II clinical study of telitacicept (RC18) for the treatment of Primary Sjögren's Syndrome (pSS) in adults in the top international medical journal Rheumatology. The study, led by Professor Zeng Xiaofeng, demonstrated significant improvements in disease activity index scores, promising clinical benefits, and well-tolerated treatment. Telitacicept shows great potential as a breakthrough treatment for pSS.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
FAQ
When was RemeGen Co. Ltd. founded?
RemeGen Co. Ltd. was established in 2008.
What are the key therapeutic areas of focus for RemeGen?
RemeGen primarily focuses on autoimmune diseases, oncology, and ophthalmic conditions.
What are some of the notable products developed by RemeGen?
RemeGen has developed innovative antibody-drug conjugates (ADCs) such as Disitamab Vedotin (RC48) and RC88.
Where is RemeGen Co. Ltd. headquartered?
RemeGen Co. Ltd. is headquartered in Yantai, China.
What is the mission of RemeGen Co. Ltd.?
RemeGen is dedicated to providing effective treatments for patients with life-threatening illnesses through cutting-edge biologic drugs.
REMEGEN CO LTD UNSP/ADR
OTC:REGMY
REGMY Rankings
REGMY Stock Data
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
United States of America